A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fed Bioequivalence of Oxycodone Tamper Resistant (OTR) 10-mg Tablets to OxyContin 10-mg Tablets.

Trial Profile

A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fed Bioequivalence of Oxycodone Tamper Resistant (OTR) 10-mg Tablets to OxyContin 10-mg Tablets.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2010

At a glance

  • Drugs Oxycodone (Primary)
  • Indications Cancer pain; Pain; Postoperative pain
  • Focus Pharmacokinetics
  • Sponsors Purdue Pharma
  • Most Recent Events

    • 11 May 2010 Actual patient number (85) added as reported by ClinicalTrials.gov.
    • 09 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top